Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Short-Term Debt issuances (2016 - 2024)

Pediatrix Medical (MD) has disclosed Short-Term Debt issuances for 15 consecutive years, with $65.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Short-Term Debt issuances fell 68.29% to $65.0 million in Q2 2024 year-over-year; TTM through Mar 2025 was $65.0 million, a 84.69% decrease, with the full-year FY2024 number at $235.5 million, down 49.89% from a year prior.
  • Short-Term Debt issuances was $65.0 million for Q2 2024 at Pediatrix Medical, down from $170.5 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $515.0 million in Q1 2020 to a low of $12.5 million in Q2 2020.
  • A 4-year average of $187.5 million and a median of $199.5 million in 2022 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 0.68% in 2020; the steepest drop was 96.71% in 2020.
  • Pediatrix Medical's Short-Term Debt issuances stood at $12.5 million in 2020, then soared by 1144.0% to $155.5 million in 2022, then crashed by 68.49% to $49.0 million in 2023, then surged by 32.65% to $65.0 million in 2024.
  • Per Business Quant, the three most recent readings for MD's Short-Term Debt issuances are $65.0 million (Q2 2024), $170.5 million (Q1 2024), and $49.0 million (Q3 2023).